Evidence map›Paper›PMID 39204446›Full record

ArticlePharmaceutics2024

Population Pharmacokinetic-Pharmacodynamic Analysis of a Reserpine-Induced Myalgia Model in Rats.

Gloria M Alfosea-Cuadrado, Javier Zarzoso-Foj, Albert Adell, Alfonso A Valverde-Navarro, Eva M González-Soler, Víctor Mangas-Sanjuán, Arantxa Blasco-Serra

Abstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gloria M Alfosea-CuadradoDepartment of Human Anatomy and Embryology, University of Valencia, 46010 Valencia, Spain.
Javier Zarzoso-FojDepartment of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, 46100 Valencia, Spain.ORCID 0009-0007-4799-9076
Albert AdellSystems Neurobiology, Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC), Spanish National Research Council (CSIC), 39011 Santander, Spain.ORCID 0000-0003-0570-4931
Alfonso A Valverde-NavarroDepartment of Human Anatomy and Embryology, University of Valencia, 46010 Valencia, Spain.
Eva M González-SolerDepartment of Human Anatomy and Embryology, University of Valencia, 46010 Valencia, Spain.ORCID 0000-0002-4092-6962
Víctor Mangas-SanjuánDepartment of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, 46100 Valencia, Spain.ORCID 0000-0002-3388-5023
Arantxa Blasco-SerraDepartment of Human Anatomy and Embryology, University of Valencia, 46010 Valencia, Spain.ORCID 0000-0002-4040-3117

Funding

Generalitat Valenciana CIGE/2022/148Generalitat Valenciana GV/2018/049
6 · The paper itself

Abstract

(1) Background: Fibromyalgia syndrome (FMS) is a chronic pain condition with widespread pain and multiple comorbidities, for which conventional therapies offer limited benefits. The reserpine-induced myalgia (RIM) model is an efficient animal model of FMS in rodents. This study aimed to develop a pharmacokinetic-pharmacodynamic (PK-PD) model of reserpine in rats, linking to its impact on monoamines (MAs). (2) Methods: Reserpine was administered daily for three consecutive days at dose levels of 0.1, 0.5, and 1 mg/kg. A total of 120 rats were included, and 120 PK and 828 PD observations were collected from 48 to 96 h after the first dose of reserpine. Non-linear mixed-effect data analysis was applied for structural PK-PD model definition, variability characterization, and covariate analysis. (3) Results: A one-compartment model best described reserpine in rats (V = 1.3 mL/kg and CL = 4.5 × 10

Indexed as

fibromyalgiapharmacodynamicpharmacokineticreserpine

Identifiers

PMID39204446
PMCPMC11359992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.